2011Journal of Bengbu Medical CollegeRequires access

Clinical analysis of Serum HE4 by chemiluminescence method in 46 patients with ovarian cancer

Ge Xin

Open publisher page 0 citations

Abstract

Objective:To explore the value of human epididymis protein 4(HE4) in diagnosis of ovarian cancer in different clinical stages,and determine whether HE4 is better than cancer antigen 125(CA125),another tumor marker of ovarian cancer.Methods:The serum HE4 levels in 46 patients with ovarian cancer(among them,the numbers of early,intermediate and terminal cancer were 9,31 and 6,respectively),50 patients with benign ovarian tumour and 50 healthy women were measured by automatic chemiluminescence method.Results:The level of serum HE4 was significantly higher in ovarian cancer patients than those in other two groups(P0.01).In 9 early ovarian cancer patients,the positive rate of HE4 was 78%,which was significantly higher than CA125,the positive rate was 55%.Conclusions:HE4 is a specific marker and it is better than CA125 in diagnosis of ovarian cancer,especially it is important for diagnosis of early ovarian cancer.

About this research paper

What this paper is about

Objective:To explore the value of human epididymis protein 4(HE4) in diagnosis of ovarian cancer in different clinical stages,and determine whether HE4 is better than cancer antigen 125(CA125),another tumor marker of ovarian cancer.Methods:The serum HE4 levels in 46 patients with ovarian cancer(among them,the numbers of early,intermediate and terminal cancer were 9,31 and 6,respectively),50 patients with benign ovarian tumour and 50 healthy women were measured by automatic chemiluminescence method.Results:The level of serum HE4 was significantly higher in ovarian cancer patients than those in other two groups(P0.01).In 9 early ovarian cancer patients,the positive rate of HE4 was 78%,which was significantly higher than CA125,the positive rate was 55%.Conclusions:HE4 is a specific marker and it is better than CA125 in diagnosis of ovarian cancer,especially it is important for diagnosis of early ovarian cancer.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To explore the value of human epididymis protein 4(HE4) in diagnosis of ovarian cancer in different clinical stages,and determine whether HE4 is better than cancer antigen 125(CA125),another tumor marker of ovarian cancer.Methods:The serum HE4 levels in 46 patients with ovarian cancer(among them,the numbers of early,intermediate and terminal cancer were 9,31 and 6,respectively),50 patients with benign ovarian tumour and 50 healthy women were measured by automatic chemiluminescence method.Results:The level of serum HE4 was significantly higher in ovarian cancer patients than those in other two groups(P0.01).In 9 early ovarian cancer patients,the positive rate of HE4 was 78%,which was significantly higher than CA125,the positive rate was 55%.Conclusions:HE4 is a specific marker and it is better than CA125 in diagnosis of ovarian cancer,especially it is important for diagnosis of early ovarian cancer.

Key concepts: Medicine, Ovarian cancer, Epididymis, Tumor marker, Cancer antigen, Cancer, Oncology, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical analysis of Serum HE4 by chemiluminescence method in 46 patients with ovarian cancer — Research Paper | ScholarLens